• PepGen will move PGN-EDODM1 into the highest-dose cohort in its Phase 2 FREEDOM2-DM1 study following a DSMB safety review.
• The DSMB also supported raising dosing in the open-label extension, reinforcing a safety profile that has remained broadly acceptable with repeat treatment.
• No serious adverse events, dose-limiting toxicities, cumulative toxicity signals, or treatment discontinuations have been reported so far in FREEDOM2 or the extension.
• Results from the fully enrolled 10 mg/kg cohort are scheduled for November; 12.5 mg/kg cohort results are expected in 1H 2027.
• An end-of-Phase 2 regulatory meeting is planned in 1H 2027 to discuss a registrational program; an extension update is expected by early January.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PepGen Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.